Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06082349

The N-LVA Study: RCT Comparing LVA vs. Sham Surgery in Cancer-related Lymphedema

Led by Maastricht University Medical Center · Updated on 2026-01-16

110

Participants Needed

3

Research Sites

271 weeks

Total Duration

On this page

Sponsors

M

Maastricht University Medical Center

Lead Sponsor

R

Radboud University Medical Center

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this randomized controlled trial is to compare the effectiveness and cost-effectiveness of lymphaticovenous anastomosis (LVA) with sham surgery for patients suffering from unilateral cancer-related lymphedema in either the upper or lower extremity. It aims to answer whether LVA is more effective than sham surgery in terms of improvement in Lymph-ICF score. A total of 110 participants will be allocated randomly into two groups at a 1:1 ratio. The first group will receive lymphaticovenous anastomosis (LVA), while the second group will undergo sham surgery.

CONDITIONS

Official Title

The N-LVA Study: RCT Comparing LVA vs. Sham Surgery in Cancer-related Lymphedema

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Treated for cancer and underwent treatment of either axillary or inguinal lymph nodes or radiotherapy
  • Early stage lymphedema (ISL I-II) in the upper or lower extremity, diagnosed by lymphoscintigraphy for the lower extremity
  • Unilateral lymphedema
  • Viable lymphatic vessels as determined by indocyanine green (ICG) lymphography (stage II-III)
  • Refractory lymphedema after at least three months of conservative treatment
  • Provided informed consent
Not Eligible

You will not qualify if you...

  • History of lymphatic reconstruction in the past 10 years
  • Late-stage lymphedema of the extremity (ISL classification 65 II) with fat deposition and/or fibrosis
  • Active distant metastases treated with palliative intent
  • Currently receiving active treatment for primary cancer such as surgery, radiotherapy, or chemotherapy (adjuvant targeted or endocrine treatment allowed)
  • Edema due to venous insufficiency confirmed by venous duplex ultrasound
  • Active infection in the lymphedematous limb
  • Bilateral lymphedema
  • Lymphedema limited to genital or breast area only
  • Primary lymphedema
  • Non-viable lymphatic system as determined by ICG lymphography (stages IV and V)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands, 6525GA

Actively Recruiting

2

Maastricht University Medical Center

Maastricht, Limburg, Netherlands, 6229HX

Actively Recruiting

3

Erasmus University Medical Center

Rotterdam, South Holland, Netherlands, 3015GD

Actively Recruiting

Loading map...

Research Team

T

Tanya Wolffenbuttel, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here